Literature-reported formulation composition
Component: A4B4-S3 | mol%: 50 | Role: Ionizable lipid
sales@dcchemicals.com
Lipid A4B4-S3
Literature records
Search the tables and observations reproduced from the product literature guide. Rows may represent measurements, recipes or experimental context; they are not all independent experiments.
Literature-reported formulation composition
Component: DSPC | mol%: 10 | Role: Helper phospholipid
Literature-reported formulation composition
Component: Cholesterol | mol%: 38.5 | Role: Sterol
Literature-reported formulation composition
Component: C14-PEG2000 | mol%: 1.5 | Role: PEG lipid
Literature-reported formulation composition
Component: Reported total | mol%: 100 | Role: Source values retained
Reported observation
Literature-reported IM luciferase mRNA delivery A4B4-S3 outperformed H2A4B4 and A4B4-S4 in the reported comparison. 0.05 mg/kg luciferase mRNA; n=3 · H2A4B4 and A4B4-S4 PMC article, Fig. 3I
Reported observation
Literature-reported Cre-mediated liver editing CD45−/CD31− nonhematopoietic/nonendothelial population editing was 56% for A4B4-S3 versus 48% for SM-102; overall immune-cell editing was 34% versus 28%. Ai9 mice; 0.5 mg/kg Cre mRNA on days 0 and 3; liver readout day 5 · SM-102 PMC article, Fig. 3J and text
Reported observation
Literature-reported hEPO protein replacement A4B4-S3 produced the highest reported hEPO peak among the compared formulations and maintained repeat-dose peaks in the five-dose schedule. 0.25 mg/kg hEPO mRNA retro-orbital IV; peak at 6 h; every 7 days ×5 · A4B4-S4 and SM-102 PMC article, hEPO section and Fig. 3L-M
Reported observation
Literature-reported Repeat-dose safety The article reports no significant ALT/AST or H&E abnormalities in the tested repeat-dose mouse study. Five weekly hEPO mRNA doses · Comparator LNP groups PMC article safety narrative; SI Fig. S14 is referenced but not accessed